Risk of significant cytopenias after treatment with tocilizumab in systemic juvenile arthritis patients with a history of macrophage activation syndrome

被引：14

作者：

Kessler, Elizabeth A. ^{[1
]}

Vora, Sheetal S. ^{[1
]}

Verbsky, James W. ^{[1
,2
]}

机构：

[1] Med Coll Wisconsin, Dept Pediat, Div Rheumatol, Milwaukee, WI 53226 USA

[2] Childrens Corp Ctr, Milwaukee, WI 53226 USA

来源：

PEDIATRIC RHEUMATOLOGY | 2012年 / 10卷

关键词：

Juvenile idiopathic arthritis; Macrophage activation syndrome; Tocilizumab; IDIOPATHIC ARTHRITIS; EFFICACY; CHILDREN; TRIAL;

D O I：

10.1186/1546-0096-10-30

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

Tocilizumab (TCZ) is the first FDA-approved treatment for systemic juvenile idiopathic arthritis (sJIA). We report 3 cases of cytopenias in children with sJIA treated with TCZ. Two of the children who developed significant cytopenias shortly after initiation of TCZ had a history of macrophage activation syndrome. We raise the possibility that patients with a tendency towards MAS have an increased risk of developing cytopenias when treated with tocilizumab.

引用

页数：4

共 8 条

[1]

Behrens EM, 2007, J RHEUMATOL, V34, P1133

[2]

De Benedetti F, 2010, ARTHRITIS RHEUM S10, V62, P1434

[3]

Grom AA, 2011, TXB PEDIAT RHEUMATOL, P674

[4] Juvenile idiopathic arthritis [J].

Ravelli, Angelo ;

Martini, Alberto .

LANCET, 2007, 369 (9563) :767-778

[5] Tocilizumab masks the clinical symptoms of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome: The diagnostic significance of interleukin-18 and interleukin-6 [J].

Shimizu, Masaki ;

Nakagishi, Yasuo ;

Kasai, Kazuko ;

Yamasaki, Yuichi ;

Miyoshi, Mari ;

Takei, Syuji ;

Yachie, Akihiro .

CYTOKINE, 2012, 58 (02) :287-294

[6] Open label phase II trial of single, ascending doses of MRA in Caucasian children with severe systemic juvenile idiopathic arthritis: proof of principle of the efficacy of IL-6 receptor blockade in this type of arthritis and demonstration of prolonged clinical improvement [J].

Woo, P ;

Wilkinson, N ;

Prieur, AM ;

Southwood, T ;

Leone, V ;

Livermore, P ;

Wythe, H ;

Thomson, D ;

Kishimoto, T .

ARTHRITIS RESEARCH & THERAPY, 2005, 7 (06) :R1281-R1288

[7] Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial [J].

Yokota, Shumpei ;

Imagawa, Tomoyuki ;

Mori, Masaaki ;

Miyamae, Takoko ;

Aihara, Yukoh ;

Takei, Shuji ;

Iwata, Naomi ;

Umebayashi, Hiroaki ;

Murata, Takuji ;

Miyoshi, Mari ;

Tomiita, Minako ;

Nishimoto, Norihiro ;

Kishimoto, Tadamitsu .

LANCET, 2008, 371 (9617) :998-1006

[8] Therapeutic Efficacy of Humanized Recombinant Anti-Interleukin-6 Receptor Antibody in Children With Systemic-Onset Juvenile Idiopathic Arthritis [J].

Yokota, Shumpei ;

Miyamae, Takako ;

Imagawa, Tomoyuki ;

Iwata, Naomi ;

Katakura, Shigeki ;

Mori, Masaaki ;

Woo, Patricia ;

Nishimoto, Norihiro ;

Yoshizaki, Kazuyuki ;

Kishimoto, Tadamitsu .

ARTHRITIS AND RHEUMATISM, 2005, 52 (03) :818-825

← 1 →